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To determine the sites in the m-opioid receptor
(MOR) critical for agonist-dependent desensitization,
we constructed and coexpressed MORs lacking poten-
tial phosphorylation sites along with G-protein acti-
vated inwardly rectifying potassium channels com-
posed of Kir3.1 and Kir3.4 subunits in Xenopus oocytes.
Activation of MOR by the stable enkephalin analogue,
[D-Ala2,MePhe4,Glyol5]enkephalin, led to homologous
MOR desensitization in oocytes coexpressing both G-
protein-coupled receptor kinase 3 (GRK3) and b-arres-
tin 2 (arr3). Coexpression with either GRK3 or arr3
individually did not significantly enhance desensitiza-
tion of responses evoked by wild type MOR activation.
Mutation of serine or threonine residues to alanines in
the putative third cytoplasmic loop and truncation of
the C-terminal tail did not block GRK/arr3-mediated
desensitization of MOR. Instead, alanine substitution
of a single threonine in the second cytoplasmic loop to
produce MOR(T180A) was sufficient to block homolo-
gous desensitization. The insensitivity of MOR(T180A)
might have resulted either from a block of arrestin
activation or arrestin binding to MOR. To distinguish
between these alternatives, we expressed a dominant
positive arrestin, arr2(R169E), that desensitizes G pro-
tein-coupled receptors in an agonist-dependent but
phosphorylation-independent manner. arr2(R169E)
produced robust desensitization of MOR and MOR-
(T180A) in the absence of GRK3 coexpression. These
results demonstrate that the T180A mutation probably
blocks GRK3- and arr3-mediated desensitization of
MOR by preventing a critical agonist-dependent recep-
tor phosphorylation and suggest a novel GRK3 site of
regulation not yet described for other G-protein-cou-
pled receptors.
Opiates are the drugs of choice for the treatment of chronic
pain, and a better understanding of the mechanisms underly-
ing tolerance to opioids will undoubtedly lead to greater clinical
utility. The molecular basis of tolerance manifests as a reduc-
tion in opioid agonist efficacy as demonstrated by a reduction in
the rate of G-protein activation by the agonist-bound receptor
complex (1–3). Furthermore, the modest reduction in cell sur-
face receptor does not account for the observed decrease in
agonist efficacy that accompanies tolerance measured biochem-
ically (4, 5), cytochemically (6), or electrophysiologically (7).
One mechanism of opioid receptor desensitization may be a
receptor uncoupling from its effector system caused by receptor
phosphorylation by a G-protein receptor kinase (GRK)1 and
subsequent binding of an arrestin.
The process of G-protein-coupled receptor (GPCR) desensiti-
zation can be resolved as a series of steps leading from GPCR
activation to receptor uncoupling, internalization, and receptor
recycling (Table I). This model has evolved from the studies
done in a large number of laboratories but principally champi-
oned by the Lefkowitz group using the b-adrenergic receptor
signaling as a prototypic GPCR (8, 9). In this scheme, GRKs
phosphorylate the agonist-activated GPCR (8, 9). The phospho-
rylated GPCR induces a conformational change in arrestin,
leading to arrestin activation (step 4), which unmasks arres-
tin’s GPCR binding site and allows arrestin to bind the agonist-
bound state of the GPCR (10–12). Arrestin binding then un-
couples the GPCR from its effector by sterically blocking
G-protein binding. Arrestin can also promote receptor internal-
ization by serving as an adapter linking the GPCR-arrestin
complex to dynamin and the clathrin-mediated endocytotic ma-
chinery (8, 9). The internalized GPCR-arrestin complex can
subsequently be recycled to the plasma membrane in its pre-
activated state following receptor dephosphorylation and dis-
assembly of the complex. Alternatively, the arrestin-GPCR
complex can be targeted to lysosomes for receptor degradation
(8, 9).
We previously reported that homologous desensitization of
MOR can be mediated by GRK and arrestin (13, 14). When
MOR is coexpressed in the Xenopus oocyte heterologous gene
expression system with G-protein-gated inwardly rectifying
potassium channels Kir3 (Kir3.1/3.4), receptor activation by the
selective MOR agonist, DAMGO, elicits a sustained increase in
potassium conductance. Additional expression of both GRK3
and arr3 led to a dramatic increase in the desensitization rate
of this MOR response (13, 14).
Strong evidence for a critical GRK phosphorylation site in
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the C-terminal tail of MOR necessary for homologous MOR
desensitization exists, although it remains a matter of contro-
versy. Depending on both the expression system and the MOR
agonist used, Thr394 (15–18) or Thr354, Ser355, Ser356, and
Thr357 (19) or Ser356 and Thr358 (20), when substituted with
alanines, have separately been shown to block MOR desensiti-
zation by GRKs and arrestins. Differences in the intrinsic
GRKs and arrestins in the cell lines used may have caused the
apparent discrepancies between the studies. In addition, the
desensitization assays used did not clearly distinguish between
a change in opioid tolerance caused by receptor uncoupling,
internalization, and impaired receptor recycling. Our goal then
was to dissect GRK- and arrestin-mediated regulation of MOR
in a simpler system to more specifically define the critical GRK
phosphorylation sites required for homologous MOR desensiti-
zation. To this end, we constructed MOR mutants lacking po-
tential GRK phosphorylation sites and asked whether GRK3-
and arrestin 3-dependent desensitization of MOR was affected.
EXPERIMENTAL PROCEDURES
Chemicals—DAMGO was from Peninsula Laboratories. Naloxone
was from Research Biochemicals International. [3H]CTAP was from
Multiple Peptide Systems. All other chemicals were from Sigma.
Mutagenesis of MOR—The rat MOR cDNA described previously (13,
14) was subcloned into the HindIII site of pBluescript (Stratagene),
which was used for one of three PCR-based site-directed mutagenesis
protocols described previously (21, 22). Depending on the protocol used,
appropriate pairs of sense and antisense oligonucleotides and/or oligo-
nucleotides designed to target the 59- and 39-ends of the MOR cDNA
were used to generate the described deletions or substitutions of the
MOR cDNA. The sense oligonucleotides for the site-directed mutagen-
esis were as follows: ttacgactcaaggccgttcgcatgctagcgggcgccaaagaa
(S261A/S266A/S268A) D47) gatacgccaaaatgaaggcggccgccaaca (T97A/
T101A/T103A), and gccctggatttccgtgccccccgaaatgccaaaatcgttaacgtc
(T180A). An adaptation of the QuickChange protocol from Stratagene
was used to substitute serines 190, 195, and 195 to alanine. MOR(T97A/
T101A/T103A) and MOR(T180A) cDNAs were made using the polym-
erase chain reaction overlap extension method (23). The resulting PCR
products were subcloned into pGEM-T from Promega. All MOR cDNA
templates for RNA synthesis were amplified from corresponding mu-
tagenized clones using a 59 oligonucleotide (aatctagcatttaggtgacactata-
gaataggggccatggacagcac) that introduced an SP6 transcriptional recog-
nition site and a 39 oligonucleotide (t30agggcaatggagcagtttc) that int-
roduced a 39 poly(A) tail. In the same manner, using the 59 oligonuc-
leotide above and a 39 oligonucleotide (t30tcatggatgcagaactctctgaagca),
we introduced a stop site corresponding to a 47-amino acid truncation of
the translated MOR for the construction of MOR(S261A/S266A/S268A)
D47 and MOR D47. All MOR mutations were confirmed by sequencing.
Complementary DNA Clones and cRNA Synthesis—All cDNA clones
used in this study were described previously (14, 23). T7, T3, or SP6
mMESSAGE MACHINE kits (Ambion, Austin, TX) were used to gen-
erate capped cRNAs from the PCR templates of WT MOR and MOR
mutants described under “Mutagenesis of MOR” or from linearized
plasmid templates for rat GRK3 and bovine arr3.
Oocyte Culture and Injection—Defolliculated, stage IV oocytes were
prepared as described (13). cRNA was injected (50 nl/oocyte) using a
Drummond automatic microinjector, and then oocytes were incubated
at 18 °C for 3–4 days in normal oocyte saline buffer (96 mM NaCl, 2 mM
KCl, 1 mM MgCl2, 1 mM CaCl2, and 5 mM HEPES, pH 7.5) solution
supplemented with sodium pyruvate (2.5 mM) and gentamycin (50
mg/ml).
Electrophysiology—Oocytes were clamped at 280 mV with two elec-
trodes filled with 3 M KCl having resistances of 0.5–1.5 ohms using a
Geneclamp 500 amplifier and pCLAMP 6 software (Axon Instruments,
Foster City, CA). Data were digitally recorded (Digidata 1200 (Axon
Instruments) and an Intel 386 PC) and filtered. Membrane current
traces were also recorded using a chart recorder. To facilitate the
inward potassium current flow through the Kir3 channels, normal
oocyte saline buffer (ND96) was modified to increase the KCl concen-
tration to 16 mM, and the NaCl concentration was decreased
correspondingly.
Whole Oocyte [3H]CTAP Binding—Oocytes were injected with 0.05
ng of MOR, 0.25 ng of GRK3, and 5 ng of arr3 cRNA and then 3 days
later were either untreated or pretreated for 1 h with 1 mM DAMGO and
washed three times with room temperature ND96. Each group was then
incubated for 20 min in 20 nM [3H]CTAP (0.25 mCi/mmol) in ND96 at
4 °C. Four oocytes per group were placed on Whatman GF/C 25-mm
circular glass microfiber filter paper under vacuum pressure and
washed twice with 500 ml of cold ND96 and placed in 2.5-ml Ecolite
scintillation fluid (ICN) for quantification of bound [3H]CTAP.
Statistical Analysis—Student’s t test (with two-tailed p values) was
used for comparison of the independent mean values. Dose-response
curves were fitted to a simple Emax model using NFIT software (Island
Products, Galveston, TX).
RESULTS
GRK3- and arr3-mediated Desensitization of the MOR—As
described previously (13, 14), in oocytes injected with MOR,
Kir3.1, and Kir3.4, DAMGO activation of MOR led to an in-
crease in Kir3 current. Provided MOR expression was relatively
low and both channel subunits, Kir3.1 and Kir3.4, were coex-
pressed, this MOR activation of Kir3 was remarkably stable,
with only slight decreases in responsiveness during treatments
as long as 12 h (14). This is in contrast to previous reports in
which MOR activation of Kir3 currents in Xenopus oocytes,
desensitized rapidly (up to 60% in 4 min) when MOR was
expressed with Kir3.1 alone or when MOR was expressed at
relatively high levels (24, 25). Under these latter conditions,
the reduction in current observed was demonstrated to be
heterologous desensitization, probably by receptor-independ-
ent channel inactivation (25). Thus, for this study the expres-
sion system was deliberately manipulated to minimize heter-
ologous desensitization and to optimize the sensitivity of the
system to homologous (GRK3- and arr3-mediated) desensitiza-
tion of MOR. In addition, levels of MOR expression were ad-
justed to avoid the confounding effects of spare receptors.
As previously reported, coexpression of GRK3 and arr3 led to
a marked decrease in MOR responsiveness after pretreatment
with DAMGO (Fig. 1B) (13, 14). Peak MOR responses from
oocytes injected with cRNA for MOR, Kir3.1, and Kir3.4, or also
with GRK3 or arr3 cRNA under the two-electrode voltage
clamp configuration were measured in oocytes clamped at 280
mV. Oocytes from each group were then incubated in 1 mM
DAMGO for 30–60 min. Each oocyte was then washed for 10
min in normal oocyte saline buffer (ND96), and the peak MOR
response to 1 mM DAMGO after agonist pretreatment was
measured and compared with the response prior to DAMGO
incubation. In oocytes injected with MOR and Kir3, responses
after DAMGO treatment were greater than 75% of the pre-
treatment values, and expression of GRK3 or arr3 alone did not
significantly alter the MOR desensitization (Fig. 1B). Repre-
sentative traces of the MOR responses measured before and
after DAMGO treatments are displayed in Fig. 1A. In contrast,
coexpression of GRK3 and arr3 increased the extent of MOR
desensitization (Fig. 1) as described previously (13, 14). The
rate of desensitization was found to be most dependent on the
levels of arr3 expression. For example, increasing the amount
of cRNA injection for arr3 with the same levels of GRK3 cRNA
injected led to MOR responses that desensitized to similar
extents in less than 10 min (14). Conversely, decreasing the
TABLE I
Lefkowitz model of GRK and arrestin regulation of
G-protein-coupled receptors
Step Action
1 Agonist activation of GPCR
2 GRK phosphorylation of agonist activated
GPCR
3 Arrestin activation




6 GPCR recycling or degradation
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arr3 cRNA injected required much longer DAMGO incubations
for the same degree of MOR desensitization to occur (13).
To determine whether the reduction in apparent MOR re-
sponsiveness was caused by receptor internalization, we per-
formed [3H]CTAP binding assays with whole oocytes under the
same conditions in which MOR desensitization was measured
electrophysiologically. [3H]CTAP is an antagonist; thus, it will
not induce desensitization. Also, it is a charged peptide; thus, it
will label only cell surface receptors (26). [3H]CTAP binding
was significantly higher in oocytes expressing MOR than in
uninjected oocytes (Fig. 1C). After treatment with 1 mM
DAMGO for 60 min, specific binding of [3H]CTAP was not
significantly changed in oocytes expressing MOR, GRK3, and
arr3. This result demonstrates that the reduction in response
seen electrophysiologically was not caused by receptor
internalization.
Dose-Response Relationships of WT MOR and MORs Lacking
Potential GRK3 Phosphorylation Sites in the C-terminal Tail or
the Third Cytoplasmic Loop—To determine the critical phos-
phorylation sites important for the GRK3- and arr3-dependent
desensitization described above, we began by removing the
serines and threonines in the C-terminal tail by introducing a
stop codon at residue 352 of MOR; MOR D47 lacks the last 47
amino acids (Fig. 2A). In addition, we substituted three of the
serines in the third cytoplasmic loop of MOR (S261A/S266A/
S268A) and introduced the C-terminal truncation resulting in
MOR L3D47 (Fig. 2A). Cumulative dose-response curves to
DAMGO for WT MOR, MOR L3, MOR D47, and MOR L3D47
were generated (Fig. 2B). EC50 values for DAMGO activation of
WT MOR, MOR D47, and MOR L3D47 were not significantly
different. The result indicates that the binding affinity and
intrinsic efficacy of MOR were not significantly altered by the
respective alanine substitutions or truncations (Fig. 2B).
GRK3- and arr3-mediated Desensitization of MORs Lacking
Potential GRK3 Phosphorylation Sites in the Third Cytoplas-
mic Loop and C-terminal Tail—GRK3 phosphorylation of the
third cytoplasmic loop or the C-terminal tail has repeatedly
been implicated in desensitization of G-protein-coupled recep-
tors, and strong evidence exists for a critical role of the C-
terminal tail in MOR desensitization (15–20). Thus, we coex-
pressed GRK3 and arr3 with WT MOR and MOR D47 to
determine if the serines and threonines in the C-terminal tail
were required for GRK3- and arr3-mediated desensitization of
MOR in the Xenopus oocyte expression system. As with the WT
MOR, MOR D47 did not desensitize significantly in the absence
of GRK3 and arr3 expression. However, when coexpressed with
GRK3 and arr3, MOR D47 desensitized at rate that was indis-
tinguishable from WT MOR. The result demonstrates that the
serine and threonine residues in the C-terminal tail were not
necessary for GRK3- and arr3-mediated desensitization in this
system. To determine whether either residues in the third
cytoplasmic loop or the C-terminal tail were sufficient for
GRK3- and arr3-mediated desensitization of MOR, we com-
pared the desensitization of WT MOR and MOR L3D47, which
lacked potential GRK3 phosphorylation sites in the third cyto-
plasmic loop and the C-terminal tail. As before, MOR L3D47
expression by itself did not lead to significant receptor desen-
sitization. Coexpression of GRK3 and arr3 with MOR L3 D47,
however, caused a MOR L3D47 desensitization that was indis-
tinguishable from GRK3- and arr3-dependent desensitization
of the wild type MOR. These data suggest that GRK3- and
arr3-dependent desensitization of MOR in this system did not
require phosphorylation of the third cytoplasmic loop or the
C-terminal tail of MOR.
Dose-Response Relationships of WT MOR and MORs Lacking
Potential GRK3 Phosphorylation Sites in the First and Second
Cytoplasmic Loop—Since alanine substitution or removal of
potential GRK3 phosphorylation sites of MOR in the third
cytoplasmic loop and the C-terminal tail failed to block GRK3-
FIG. 1. GRK3- and arr3-mediated desensitization of MOR. A,
left to right, representative current traces from oocytes injected with
0.05 ng of MOR cRNA and 0.02 ng of each Kir3.1 and Kir3.4, also
injected with 0.25 ng of GRK3, 5 ng of arr3, or both GRK3 and arr3. A,
top, response to 1 mM DAMGO of above groups. Bottom, response to 1 mM
DAMGO after a 30- or 60-min DAMGO incubation and 10-min wash in
ND96. MOR responses in oocytes expressed with GRK3 and arr3 dif-
fered from batch to batch. The amount of time required for 50% of the
WT MOR response to desensitize with GRK3 and arr3 expression was
determined and then held constant for all experiments from the same
donor on the same day. The time used in this series of experiments was
usually between 30 and 60 min. Change in the oocyte perfusion medium
from normal oocyte saline (ND96) containing 2 mM potassium to saline
containing 16 mM potassium led to an increase in inward potassium
current through the basally activated Kir. Activation of MOR by perfu-
sion with 1 mM DAMGO caused a further increase in Kir3 current in
oocyte saline buffer containing 16 mM potassium. The amount of MOR
desensitization was calculated by comparing the peak DAMGO-elicited
current before and after a 30–60-min incubation in 1 mM DAMGO and
10 min wash in ND96 and presented as the percentage of untreated
response. Calibration for each trace was 400 nA, 2 min. B, summary of
the WT MOR desensitization. DAMGO (1 mM) activation of MOR did not
produce a significant amount of MOR desensitization in the absence of
GRK3 and arr3 expression or in the presence of 0.25 ng of GRK3 or 5 ng
of arr3 alone. Coexpression of GRK3 and arr3 dramatically increased
the amount of MOR desensitization. Error bars, means 6 S.E. for 9–16
independent determinations in oocytes from three oocyte donors. **, p ,
0.01 compared with oocytes not injected with GRK3 and arr3. C,
[3H]CTAP binding in either uninjected oocytes or oocytes injected with
0.05 ng of MOR, 0.25 ng of GRK3, and 5 ng of arr3 cRNA and then either
untreated or pretreated for 1 h with 1 mM DAMGO. Following DAMGO
treatment, oocytes were washed three times with room temperature
ND96 to remove the opioid. In separate electrophysiological assays of
opioid response, this wash procedure was sufficient to completely re-
verse the effects of 1 mM DAMGO (data not shown). Each group of intact
oocytes was then incubated for 20 min in 20 nM [3H]CTAP (0.25 mCi/
mmol) in ND96 at 4 °C, washed twice with 500 ml of cold ND96, and
placed in 2.5 ml of scintillation fluid for quantification of bound
[3H]CTAP. Each bar represents the average fmol of [3H]CTAP bound to
four oocytes, from 7–10 separate determinations from two identical
experiments. Error bars, means 6 S.E.; **, p , 0.01 compared with
uninjected oocytes.
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and arr3-mediated desensitization of MOR, we next con-
structed MOR(T97A/T101A/T103A) and MOR(T180A), which
lacked potential GRK3 phosphorylation sites in the first and
second cytoplasmic loop, respectively (Fig. 3A). To ensure that
the described mutations did not alter receptor functioning, we
constructed cumulative dose-response curves to DAMGO for
WT MOR, MOR(T97A/T101A/T103A), and MOR(T180A) (Fig.
3B). EC50 values for DAMGO activation of WT MOR,
MOR(T97A/T101A/T103A), and MOR(T180A) did not signifi-
cantly differ, indicating that the receptor functioning of each
receptor mutant was intact (Fig. 3B).
GRK3- and arr3-mediated Desensitization of MORs Lacking
Potential GRK3 Phosphorylation Site in the First and Second
Cytoplasmic Loop—To determine whether the critical phospho-
rylation sites of MOR necessary for GRK3- and arr3-dependent
desensitization reside in the first or second cytoplasmic loop,
we coexpressed GRK3 and arr3 with MOR(T97A/T101A/
T103A) and MOR(T180A) and compared the rates of desensi-
tization with that of WT MOR. MOR(T97A/T101A/T103A) and
MOR(T180A) did not desensitize significantly in the absence of
GRK3 or arr3 expression (Fig. 3B). Furthermore, MOR(T97A/
T101A/T103A), when expressed with GRK3 and arr3, desensi-
tized at a rate that was indistinguishable from that of WT MOR
under the same conditions (Fig. 4B). MOR(T180A), in which a
single threonine was substituted for an alanine, however,
failed to desensitize in the presence of GRK3 and arrestin
coexpression. Instead, MOR(T180A), expressed with GRK3 and
arr3, desensitized at rate that was indistinguishable from con-
trol rates in the absence of GRK3 and arr3 expression. As a
positive control for GRK3 and arr3 expression in the oocytes
injected with MOR(T180A), Kir3, GRK3, and arr3, some of the
oocytes from the following groups were also injected with cRNA
FIG. 2. Effect of the third cytoplasmic loop and C-terminal tail mutations on DAMGO dose responses and GRK3- and arr3-
mediated desensitization. A, schematic diagrams depicting the WT MOR with serine and threonine residues represented as circles, and
summarizing alanine substitutions (marked by 3) and or truncations made in the construction of MOR L3, MOR D47, and MOR L3D47. B,
dose-response curves for DAMGO activation of MORs lacking potential phosphorylation sites in the third cytoplasmic loop and the C-terminal tail.
Oocytes were clamped at 280 mV while bathed in normal oocyte saline buffer containing 2 mM potassium. Oocytes were then superfused with a
saline buffer in which the potassium concentration was increased to 16 mM, enabling a basal inward current to flow through the Kir3 channels.
Cumulative, incrementing doses of DAMGO were applied to the bath followed by perfusion with the opioid receptor antagonist naloxone (1 mM).
The response to each dose of agonist was defined as the agonist-elicited inward current minus the basal current. The agonist response at each dose
was normalized as a percentage of the average maximal DAMGO response obtained in separate oocytes from the same group. Each point represents
the mean response measured in four to five oocytes. Oocytes were injected with 0.05–0.1 ng of the respective WT or mutant receptor cRNA along
with 0.02 ng of cRNA of each Kir3.1 and Kir3.4. Error bars, means 6 S.E.; when not shown, they are smaller than the plotted symbols. C, effect
of third cytoplasmic loop and C-terminal tail mutations on GRK3- and arr3-mediated desensitization. Pretreatment with 1 mM DAMGO did not
produce a significant amount of MOR L3D47 or MOR D47 desensitization in the absence of GRK3 and arr3 expression or in the presence of 0.5 ng
of GRK3 or 3 ng of arr3 alone. Coexpression of GRK3 and arr3 dramatically increased the rate of MOR desensitization that was not significantly
different from WT MOR desensitization expressed with GRK3 and arrestin in the same batch and treated in the same way. Experimental design
was identical to that described in the legend to Fig. 1. Error bars, means 6 S.E. for 5–10 independent determinations. **, p , 0.01 compared with
oocytes not injected with GRK3 and arr3.
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for the b2-adrenergic receptor and Gas. As previously reported,
b2-adrenergic receptor activation by isoproterenol (1 mM) acti-
vated Kir3, a response that desensitizes rapidly only in oocytes
also coexpressing GRK3 and arr3. b2-Adrenergic receptor de-
sensitization rates in the oocytes injected with WT MOR; the
WT MOR, GRK3, and arr3; and MOR(T180A), GRK3, and arr3
were 4.6 6 1.9, 18.8 6 3.8, and 16.7 6 1.7% per min, respec-
tively. The lack of significance between the latter two groups
indicates that GRK3 and arr3 expressed well in oocytes ex-
pressing MOR WT and MOR(T180A).
In addition, the lack of GRK- and arrestin-dependent desen-
sitization of MOR(T180A) was not due to receptor overexpres-
sion or a change in the intrinsic efficacy of MOR(T180A). Spe-
cific [3H]CTAP binding to oocytes injected with 0.05 ng of cRNA
for MOR WT or MOR(T180A) was not statistically different,
6.7 6 0.9 and 4.7 6 0.7 fmol bound, respectively (n 5 10). In
addition, the DAMGO-evoked peak responses measured elec-
trophysiologically were similar, 620 6 157 nA (MOR WT) and
350 6 87 nA (MOR(T180A). Thus, the lack of GRK3/arr-medi-
ated desensitization of MOR(T180A) did not result from a rel-
ative excess of MOR(T180A) expression compared with WT
MOR expression. Furthermore, the average peak MOR re-
sponse from oocytes injected with a higher dose of cRNA (0.1
ng) for each receptor was significantly higher for both receptor
responses (1320 6 1220 and 1000 6 164 nA for MOR WT and
MOR(T180A), respectively); the result demonstrated a lack of a
receptor reserve for each receptor at the dose of cRNA used.
These data suggest that MOR(T180A) failed to desensitize
because threonine 180 is required for GRK3- and arr3-depend-
ent desensitization of MOR.
Desensitization of WT MOR and MOR(T180A) by a Domi-
nant Positive Arrestin, arr2(R169E)—The insensitivity of
MOR(T180A) presumably results from the loss of a critical
GRK3 phosphorylation site. Alternatively, GRK3 could phos-
phorylate MOR(T180A) normally and activate arrestin, but the
binding of the activated arr3 to MOR(T180A) might be im-
paired. To distinguish between these alternatives, we coex-
pressed WT MOR and MOR(T180A) with a form of arrestin
FIG. 3. Effect of first and second cytoplasmic loop mutations on dose responses to DAMGO and GRK3- and arr3-mediated
desensitization of MOR. A, schematic diagrams depicting the WT MOR with serine and threonine residues represented as circles and
summarizing alanine substitutions (marked by 3) made in the construction of MOR(T97A/T101A/T103A) and MOR(T180A). B, dose-response
curves for DAMGO activation of MORs lacking potential GRK phosphorylation sites in the first and second cytoplasmic loop. Conditions were the
same as described for Fig. 2 except dose responses of MOR(T97A/T101A/T103A), MOR(T180A), and WT MOR were compared. Each point
represents the mean response measured in four to five oocytes. Oocytes were injected with 0.05–0.5 ng of the respective WT or mutant receptor
along with 0.02 ng of each Kir3.1 and Kir3.4. Error bars, means 6 S.E.; when not shown, they are smaller than the plotted symbols. C, summary
of the WT MOR, MOR(T97A/T101A/T103A), and MOR(T180A) desensitization rates either expressed alone, with 0.1–0.5 ng of cRNA for each
receptor injected, or expressed with 0.5 ng of GRK3 and 5 ng of arr3 or with 0.25 ng of GRK3 and 5 ng of arr3. Experimental conditions were
identical to those described in the legend to Fig. 1. Desensitization of MOR responses with GRK3 and arr3 were not significantly different for
MOR(T97A/T101A/T103A) compared with WT MOR expressed with GRK3 and arr3, whereas MOR(T180A) desensitization by GRK3 and arr3 was
completely blocked under the same conditions on the same day. Error bars, means 6 S.E. for 5–12 independent determinations; **, p , 0.01
compared with respective receptor desensitization not injected with GRK3 and arr3.
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known to desensitize the d opioid receptor (DOR) and the b2-
adrenergic receptor in a manner that was agonist-dependent
but GRK-independent (11). This “dominant positive” form of
arrestin does not require activation by the phosphorylated
GPCR, but it can bind and inactivate the agonist bound GPCR.
Oocytes expressing arr2(R169E) showed robust agonist-
dependent but GRK-independent, desensitization of MOR,
whereas oocytes expressing WT arr2 did not show enhanced
desensitization of MOR (Fig. 4). Furthermore, arr2(R169E)
also caused robust desensitization of MOR(T180A) that was not
statistically different from WT MOR desensitization by
arr2(R169E). This enhanced desensitization of MOR by
arr2(R169E) was not due to greater expression compared
with arr2 WT. Expression of arr2 WT and arr2(R169E) in the
oocytes used for in the desensitization experiments was found
to be 0.53 6 0.06 and 0.40 6 0.05, respectively, in the MOR
WT-expressing oocytes and 0.53 6 0.07 and 0.41 6 0.04 in the
MOR(T180A)-expressing oocytes (ng of arrestin/mg of protein 6
S.D.). These data suggest that the T180A mutation of MOR
blocks GRK3- and arrestin-mediated desensitization, not by
disrupting the arrestin binding to the receptor downstream of
GRK action but because it removed a critical agonist-depend-
ent GRK3 phosphorylation site necessary for arrestin
activation.
DISCUSSION
The principal finding of the study was that threonine 180 of
MOR was required for GRK3- and arr3-dependent homologous
desensitization of MOR expressed in Xenopus oocytes. In our
investigation, the removal of potential GRK phosphorylation
sites in all other cytoplasmic domains of MOR failed to block
MOR desensitization by GRK3 and arr3. Because receptor in-
ternalization does not contribute to the desensitization events
in this system, the study clearly focuses on the roles of GRK3
and arr3 in the initial receptor uncoupling process. In addition,
we further characterized the actions of the dominant positive
form of arrestin. Previously, we demonstrated the agonist-de-
pendent but GRK-independent desensitization of DOR and b2-
adrenergic receptor by the dominant positive arr2(R169E).
Here we report that arr2(R169E) also desensitized MOR in a
GRK-independent but agonist-dependent manner. The obser-
vation that MOR(T180A) remained sensitive to arr2(R169E)
suggested that MOR(T180A) lacked a critical GRK3 phospho-
rylation site necessary for homologous MOR desensitization.
From extensive studies of GRK and arrestin regulation of
G-protein-coupled receptors, a common theme has evolved. Ser-
ine or threonine residues in the third cytoplasmic loop or the
C-terminal tail have repeatedly been demonstrated to be re-
sponsible for the regulation of GPCRs by GRKs and arrestins.
For example, GRK phosphorylation of muscarinic acetylcholine
receptor m1 and m2 subtypes is predominately in the third
cytoplasmic loop (27, 28). In contrast, the d- and k-opioid re-
ceptors (DORs and KORs) require GRK phosphorylation of the
C-terminal tail for GRK- and arrestin-dependent desensitiza-
tion (13, 22). The difference between the critical site in MOR
and the other GPCRs cannot be attributed to the differences in
the expression system, since DOR and KOR desensitization
were also characterized using the oocyte system.
Interestingly, the finding that homologous MOR desensiti-
zation in Xenopus oocytes does not require a C-terminal tail
determinant was not the only disparity among these closely
related opioid receptor subtypes in this system. Homologous
MOR desensitization by GRK3 and arr3 proceeds with a dra-
matically slower time course compared with that of DOR and
KOR. Although the rate of MOR desensitization can be accel-
erated with increased arrestin expression, under conditions
where DOR and KOR desensitize in minutes, MOR desensiti-
zation required hours in this system (13, 22). The relatively
slow desensitization rate of MOR might result from a slower
kinetics of GRK3 phosphorylation, a less efficient activation of
arrestin, or a slower association of activated arrestin with the
GPCR. The observation that the dominant positive form of
arrestin desensitizes MOR at rates that were equivalent to
DOR and KOR desensitization rates suggests that the last
explanation is unlikely. Our hypothesis is that GRK3-phospho-
rylated MOR is a less efficient activator of arrestin than either
DOR or KOR, but this remains to be directly tested.
The findings that threonine 180 was required for the GRK-
and arrestin-mediated desensitization of MOR and that the
C-terminal tail was not involved are in sharp contrast with
studies of this type in mammalian cell line expression systems
(15–20). Although not agreeing on the exact residues responsi-
ble, prior studies of MOR desensitization in hypertransfected
mammalian cell lines have pointed to sites within the C-termi-
nal tail. The basis for the discrepancy between those studies
and this one is not clear. The results using mammalian cell
lines often rely on the intrinsic kinase and arrestins expressed;
thus, the difference could be due to differences in GRK3 and
arr3 and the unknown intrinsic proteins. The desensitization
assays using mammalian cell lines are also strongly affected by
internalization and receptor recycling rates, and overexpres-
sion of receptors produces a large opioid receptor reserve. The
contributions of each of these to the tolerance observed would
confound the measure of receptor desensitization. The receptor
domains responsible for internalization and recycling are likely
to be different from those responsible for receptor uncoupling.
This distinction has been clearly demonstrated for canna-
banoid and muscarinic acetylcholine receptors (21, 24). Fur-
thermore, as discussed by Law et al. (30), recycling of MOR in
mammalian cell lines can occur within minutes of agonist
treatment such that the number of uncoupled receptors in cells
highly overexpressing MOR may not be large enough to see a
decrease in MOR-mediated second messenger responses. In
addition, the presence of a large receptor reserve requires a
FIG. 4. arr2(R169E)-mediated desensitization of WT MOR and
MOR(T180A). Summary of the WT MOR and MOR(T180A) desensiti-
zation in oocytes expressing 0.05 ng of WT MOR or MOR(T180A) with
16 ng of arr2 WT or 16 ng of arr2(R169E). arr2(R169E) expression with
either WT MOR or MOR(T180A) caused a robust GRK-independent
desensitization of both WT MOR and MOR(T180A) to extents that were
statistically indistinguishable after 4 min of continuous perfusion with
1 mM DAMGO. With the exception of the differences described above,
experimental conditions were the same as described in Fig. 1. Error
bars, means 6 S.E. for five independent determinations; **, p , 0.01
compared with respective receptor desensitization injected with WT
arr2.
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large fraction of receptor uncoupling before a significant
change in the second messenger response can be measured.
This is supported by those who have found a lack of correlation
of MOR phosphorylation with receptor desensitization in cells
highly overexpressing MOR (31, 32). This correlation was
clearly demonstrated, however, when receptor recycling path-
ways were blocked or when the functional receptor number was
decreased with the treatment of cells with a irreversible MOR
antagonist (30). Since desensitization can potentially occur ei-
ther by receptor uncoupling or internalization, to fully under-
stand both processes it is necessary to have assays that distin-
guish these mechanisms and clearly define which is involved in
terminating the MOR response in the system used.
For this reason, we deliberately expressed levels of MOR
that were significantly less than those required to fully activate
the coexpressed Kir3. This ensured a lack of receptor reserve for
the response measured and allowed us to measure receptor
desensitization as it occurred. Furthermore, the finding that
the C-terminal tail truncation that has been shown to block
MOR internalization in mammalian cell lines did not affect
MOR desensitization in this system suggests that MOR inter-
nalization in the manner that it occurs in mammalian cell lines
is not responsible for the homologous MOR desensitization that
we observed. This conclusion is supported by the finding that
specific [3H]CTAP binding was not decreased under conditions
where MOR desensitization occurred. Therefore, it is likely
that we have defined a critical role of Thr180 of MOR necessary
for receptor uncoupling that is distinct from the role of the
C-terminal tail in MOR internalization.
Another intriguing possibility is that these data represent a
homologue-specific action of GRK3 and arr3. In the Xenopus
oocyte expression system, coexpression of GRK3 and arr3 was
required for homologous MOR desensitization, which suggests
the lack of endogenous enzymes that can substitute for either
role. This is in contrast to mammalian cell expression systems
where exogenous expression of GRK and arrestin is not re-
quired, making it difficult to clearly define roles of exogenously
or endogenously expressed GRKs and arrestins.
Receptor uncoupling and internalization of MOR represent
intimately related cellular processes that may be involved in
the development of tolerance to opioid drugs. Thus, under-
standing these processes in greater detail may enable the elu-
cidation of the roles of these processes separate from other
mechanisms of opioid tolerance such as learning and memory
and other compensatory changes in neuronal circuitry. Simi-
larly, defining markers for receptor internalization distinct
from receptor uncoupling may provide tools to elucidate the
roles of each of these processes in opioid tolerance as well as
providing multiple targets for improving the clinical use of
opioid drugs.
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